David Mehalick - Mar 4, 2025 Form 4 Insider Report for Coeptis Therapeutics Holdings, Inc. (COEP)

Role
CEO and President, Director, 10%+ Owner
Signature
/s/ David Mehalick
Stock symbol
COEP
Transactions as of
Mar 4, 2025
Transactions value $
$0
Form type
4
Date filed
3/6/2025, 05:27 PM
Previous filing
Jan 9, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COEP Non-Qualified Stock Options (right to buy) Award +28.9K +16.86% 200K Mar 4, 2025 Common Stock 28.9K $10.56 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 4, 2025, the reporting person received a grant of 28,875 non-qualified stock options, under the 2022 equity incentive plan.
F2 The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Capital Market on the day of grant.
F3 Options will vest over 4 years, in equal quarterly installments over such period, with the final options vesting on 12/31/28.
F4 Expiration date is ten years from the day of grant.